Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Abstract Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P‐glycoprotein substrate and moderate CYP3A inhibitor....

Full description

Bibliographic Details
Main Authors:	Ying Hong, Tomoko Ishizuka, Akiko Watanabe, Masaya Tachibana, Mark Lee, Hitoshi Ishizuka, Frank LaCreta, Malaz Abutarif
Format:	Article
Language:	English
Published:	Wiley 2021-11-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.13082

Similar Items

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma
by: Varsha Ananthapadmanabhan, et al.
Published: (2022-07-01)

Insights into CYP2B6-mediated drug–drug interactions
by: William D. Hedrich, et al.
Published: (2016-09-01)

A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment
by: Jonghwa Lee, et al.
Published: (2024-01-01)

Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
by: Ilia G. Denisov, et al.
Published: (2022-06-01)

The Role of CYP 450 Isozymes in Drug-Drug Interaction
by: Fatmah Bakhdar
Published: (2020-06-01)

In Vitro Assessment of CYP-Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate
by: Shaheed Ur Rehman, et al.
Published: (2016-06-01)

A Comparative Genomic and Phylogenetic Investigation of the Xenobiotic Metabolism Enzymes of Cytochrome P450 in Elephants Shows Loss in CYP2E and CYP4A
by: Kanami Watanabe, et al.
Published: (2023-06-01)

Drug-drug interactions: it is not only CYP450's which matter
by: Back David J
Published: (2010-05-01)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
by: Thomas Wendl, et al.
Published: (2022-02-01)

A systematic review and network meta‐analysis of antimanic drugs for the treatment of acute mania used in Japan
by: Kanako Ishizuka, et al.
Published: (2022-12-01)

Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report
by: Hiroki Tateishi, et al.
Published: (2021-11-01)

Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
by: Florian Klomp, et al.
Published: (2020-12-01)

Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
by: Masaya Tachibana, et al.
Published: (2023-11-01)

ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance
by: Min Chen, et al.
Published: (2023-02-01)

Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma
by: Lan Gao, et al.
Published: (2024-02-01)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
by: Eric D. Eisenmann, et al.
Published: (2022-03-01)

Regulation of CYP450 and drug transporter mediated by gut microbiota under high-altitude hypoxia
by: Xue Bai, et al.
Published: (2022-09-01)

Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib
by: Christine Bowman, et al.
Published: (2024-04-01)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
by: Jim J. Xiao, et al.
Published: (2019-01-01)

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: J. Senapati, et al.
Published: (2022-06-01)

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
by: Shan Zhou, et al.
Published: (2023-12-01)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2023-05-01)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
by: David Damoiseaux, et al.
Published: (2022-07-01)

Possible Commonalities of Clinical Manifestations Between Dystonia and Catatonia
by: Kanako Ishizuka, et al.
Published: (2022-04-01)

Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail
by: Marija Bosilkovska, et al.
Published: (2019-10-01)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
by: Saaket Agrawal, et al.
Published: (2020-09-01)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
by: Yoshiaki Kirigaya, et al.
Published: (2020-07-01)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022-04-01)

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
by: Jayastu Senapati, et al.
Published: (2023-06-01)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
by: Laura Molenaar-Kuijsten, et al.
Published: (2021-08-01)

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
by: Malavika Deodhar, et al.
Published: (2020-09-01)

Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review
by: Kenza Mansoor, et al.
Published: (2023-02-01)

Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine
by: Lara Marques, et al.
Published: (2023-05-01)

CYP3A4 mediated pharmacokinetics drug interaction potential of Maha-Yogaraj Gugglu and E, Z guggulsterone
by: Sarvesh Sabarathinam, et al.
Published: (2021-01-01)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
by: Heather Zhang, et al.
Published: (2021-12-01)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021-02-01)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
by: Denise Feick, et al.
Published: (2023-08-01)

Avian cytochrome P450 (CYP) 1-3 family genes: isoforms, evolutionary relationships, and mRNA expression in chicken liver.
by: Kensuke P Watanabe, et al.
Published: (2013-01-01)

Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer
by: Park G, et al.
Published: (2017-03-01)

Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI)
by: Bunpei Ishizuka, et al.
Published: (2021-02-01)